
Opinion|Videos|April 14, 2025
Evaluating Ruxolitinib In An 18-Month Retrospective Claims Analysis
Author(s)Gary M. Owens, MD , Lawrence Eichenfield, MD
Panelists discuss how an 18-month retrospective claims analysis evaluated ruxolitinib's real-world effectiveness in atopic dermatitis, demonstrating sustained disease control, reduced healthcare utilization, decreased steroid dependency, improved medication adherence, and consistent safety outcomes across diverse patient demographics and disease severities compared to conventional treatments.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
3
Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia
4
Step therapy requirements drive up time, costs in DME patients | ASRS 2026
5
























